Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03259503
Title Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

diffuse large B-cell lymphoma

lymphoma

Hodgkin's lymphoma

non-Hodgkin lymphoma

Therapies

Busulfan

Olaparib

Vorinostat

Palifermin

Gemcitabine

Melphalan

Dexamethasone

Pyridoxine

Rituximab

Age Groups: adult | child
Covered Countries USA


No variant requirements are available.